Clinical trial
Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)
NCT01774825 is registered in ClinicalTrials.gov with InQpharm Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)
- Lead sponsor
- InQpharm Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- February 28, 2014
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.